和元生物: 2025年半年度报告摘要

Core Viewpoint - The report highlights the ongoing challenges faced by He Yuan Biotechnology in its cell and gene therapy CDMO business, including low order prices and high operational costs, despite some improvements compared to the previous year [1][2]. Company Overview - He Yuan Biotechnology is listed on the Shanghai Stock Exchange with the stock code 688238, focusing on cell and gene therapy [2]. - As of the end of the reporting period, the total assets of the company were approximately 2.12 billion RMB, a decrease of 7.23% from the previous year [2]. Financial Performance - The company's revenue for the reporting period was approximately 119.85 million RMB, reflecting a year-on-year increase of 6.01% [3]. - The total profit for the period was a loss of approximately 102.77 million RMB, an improvement from a loss of 113.36 million RMB in the previous year [3]. - The net loss attributable to shareholders was approximately 104.57 million RMB, compared to a loss of 113.35 million RMB in the same period last year [3]. - The cash flow from operating activities showed a loss of approximately 88.50 million RMB, which is an improvement from a loss of 114.63 million RMB in the previous year [3]. - The weighted average return on net assets decreased by 0.69 percentage points to -6.35% [3]. Industry Context - The cell and gene therapy sector is identified as a key development area in the biopharmaceutical industry, supported by various national and local policies [2]. - The company aims to enhance its competitiveness and market penetration by improving R&D efficiency and expanding into new business areas [2].